Novo Nordisk A/S (NVO) Income Statement

The sequential deceleration in revenue growth, from 24.0% to 2.1% quarter-over-quarter, indicates that the extraordinary expansion driven by GLP-1 therapies may be normalizing. While 2026Q1 benefited from a strong year-over-year comparison, the 2026Q2 figure suggests a more mature growth phase. Investors should monitor whether this slowdown is a temporary blip or a sustained trend, especially as competition intensifies in the obesity and diabetes markets.

The 780 basis point sequential decline in gross margin is notable, though it remains above the peer average of approximately 80%. This could indicate increased rebates or a shift towards lower-margin products. Given the competitive landscape, sustaining gross margins above 80% may become challenging, and investors should watch for further erosion.

The dramatic drop in operating margin suggests that fixed costs, particularly R&D and SG&A, did not scale down with the revenue decline. R&D expenses surged to $17.8B in 2026Q2, up from $10.3B in the prior quarter, indicating heavy investment in pipeline development. This may signal a strategic shift towards long-term growth, but it compresses near-term profitability.

The doubling of R&D as a percentage of revenue suggests management is prioritizing future growth over current profitability. This is consistent with the need to defend against competitors like Eli Lilly. However, such elevated spending may pressure margins if revenue growth does not accelerate. Cost discipline in SG&A, which remained relatively stable, appears secondary to R&D expansion.